| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.7326/0003-4819-124-11-199606010-00006 |
| P698 | PubMed publication ID | 8624066 |
| P2093 | author name string | Richman DD | |
| Havlir DV | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 984-994 | |
| P577 | publication date | 1996-06-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Viral dynamics of HIV: implications for drug development and therapeutic strategies | |
| P478 | volume | 124 |
| Q53486545 | A new paradigm for HIV care: ethical and clinical considerations. |
| Q28343321 | A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity |
| Q28362780 | ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1 |
| Q41486041 | Advances in antiviral therapy in dermatology |
| Q45752028 | Anti-human immunodeficiency virus drug combination strategies |
| Q33659379 | Antiinfectives update: focus on treatment and prevention of viral and associated infections |
| Q41116397 | Antiretroviral drugs for AIDS. |
| Q34185841 | Antiretroviral therapy for human immunodeficiency virus infection in 1997 |
| Q33586790 | Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients |
| Q56083699 | Antiviral drug resistance |
| Q77654970 | Candidate antiretroviral agents for use in postexposure prophylaxis |
| Q33681662 | Comparison of NucliSens and Amplicor monitor assays for quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma of persons with HIV-1 subtype A infection in Abidjan, Côte d'Ivoire |
| Q24550959 | Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase |
| Q40785138 | Detection of CMV DNA in peripheral blood leukocytes as a long-range harbinger of CMV disease in HIV-infected patients. Swiss HIV Cohort Study. |
| Q34623536 | Developing a method to derive alcohol-attributable fractions for HIV/AIDS mortality based on alcohol's impact on adherence to antiretroviral medication |
| Q43049208 | Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. |
| Q35101414 | Generation of HIV-1 and Internal Control Transcripts as Standards for an In-House Quantitative Competitive RT-PCR Assay to Determine HIV-1 Viral Load |
| Q34223088 | HIV chemotherapy |
| Q35779267 | HIV entry and fusion inhibitors |
| Q46701249 | HIV therapeutics |
| Q34876000 | HIV-1 genotypic and phenotypic resistance |
| Q41368666 | HIV-1: gambling on the evolution of drug resistance? |
| Q33825196 | Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. |
| Q45752854 | Human immunodeficiency virus infection, Part I. |
| Q54003890 | Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. |
| Q35878219 | In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues |
| Q39470193 | Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells |
| Q28343602 | Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species |
| Q45749160 | Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood. |
| Q33588535 | Managing resistance to anti-HIV drugs: an important consideration for effective disease management. |
| Q41446459 | New strategies to combat HIV drug resistance |
| Q45385918 | Optimal control of HIV-virus dynamics |
| Q46727140 | Patient-perceived barriers to antiretroviral adherence: associations with race |
| Q41203155 | Pediatric HIV infection: a primer for pharmacists |
| Q28369617 | Perspectives for the treatment of hepatitis B virus infections |
| Q33631716 | Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection |
| Q44355582 | Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs |
| Q47589124 | Probing the communication of deoxythymidine triphosphate in HIV-1 reverse transcriptase by communication maps and interaction energy studies |
| Q34122362 | Progress in HIV therapeutics and the challenges of adherence to antiretroviral therapy |
| Q43956302 | Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (revised November 3, 2000). |
| Q74319012 | Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR |
| Q73584159 | Quantification of HIV-1 viral RNA and proviral DNA by isotopic competitive PCR |
| Q39253052 | Rate-limiting Pyrophosphate Release by HIV Reverse Transcriptase Improves Fidelity |
| Q35146136 | Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors |
| Q36824026 | Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. |
| Q77603258 | Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy |
| Q34047516 | Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase |
| Q33936351 | The clinical utility of viral load monitoring in HIV infection: strengths and limitations |
| Q74773518 | The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load |
| Q28350136 | The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance |
| Q54123440 | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. |
| Q34783374 | The role of protease inhibitor therapy in children with HIV infection |
| Q41413114 | The role of viral dynamics in the pathogenesis of HIV disease and implications for antiviral therapy |
| Q35207296 | The significance of HIV viral load assay precision: a review of the package insert specifications of two commercial kits |
| Q39213460 | The value of highly active antiretroviral therapy in the prevention of mother-to-child transmission of HIV. |
| Q24247767 | Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection |
| Q54052422 | Trapping of a catalytic HIV reverse transcriptase*template:primer complex through a disulfide bond. |
| Q37538534 | Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. |
Search more.